Literature DB >> 27397541

Histone lysine methyltransferases as anti-cancer targets for drug discovery.

Qing Liu1,2,3, Ming-Wei Wang1,2,3.   

Abstract

Post-translational epigenetic modification of histones is controlled by a number of histone-modifying enzymes. Such modification regulates the accessibility of DNA and the subsequent expression or silencing of a gene. Human histone methyltransferases (HMTs)constitute a large family that includes histone lysine methyltransferases (HKMTs) and histone/protein arginine methyltransferases (PRMTs). There is increasing evidence showing a correlation between HKMTs and cancer pathogenesis. Here, we present an overview of representative HKMTs, including their biological and biochemical properties as well as the profiles of small molecule inhibitors for a comprehensive understanding of HKMTs in drug discovery.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27397541      PMCID: PMC5057236          DOI: 10.1038/aps.2016.64

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  57 in total

Review 1.  Biological methylation: selected aspects.

Authors:  G L Cantoni
Journal:  Annu Rev Biochem       Date:  1975       Impact factor: 23.643

2.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Aravind Basavapathruni; Lei Jin; P Ann Boriack-Sjodin; Christina J Allain; Christine R Klaus; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

Review 3.  Homocysteine: overview of biochemistry, molecular biology, and role in disease processes.

Authors:  Brian Fowler
Journal:  Semin Vasc Med       Date:  2005-05

Review 4.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

5.  Kinetic and catalytic mechanism of HhaI methyltransferase.

Authors:  J C Wu; D V Santi
Journal:  J Biol Chem       Date:  1987-04-05       Impact factor: 5.157

6.  Histone H3 lysine 9 methyltransferases, G9a and GLP are essential for cardiac morphogenesis.

Authors:  Masayo Inagawa; Kuniko Nakajima; Tomoyuki Makino; Satoko Ogawa; Mizuyo Kojima; Satomi Ito; Aiko Ikenishi; Toshinori Hayashi; Robert J Schwartz; Kazuomi Nakamura; Tetsuya Obayashi; Makoto Tachibana; Yoichi Shinkai; Kazuhiro Maeda; Sachiko Miyagawa-Tomita; Takashi Takeuchi
Journal:  Mech Dev       Date:  2013-07-24       Impact factor: 1.882

7.  The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.

Authors:  Kevin W Kuntz; John E Campbell; Heike Keilhack; Roy M Pollock; Sarah K Knutson; Margaret Porter-Scott; Victoria M Richon; Chris J Sneeringer; Tim J Wigle; Christina J Allain; Christina R Majer; Mikel P Moyer; Robert A Copeland; Richard Chesworth
Journal:  J Med Chem       Date:  2016-01-27       Impact factor: 7.446

8.  Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294.

Authors:  Yanqi Chang; Xing Zhang; John R Horton; Anup K Upadhyay; Astrid Spannhoff; Jin Liu; James P Snyder; Mark T Bedford; Xiaodong Cheng
Journal:  Nat Struct Mol Biol       Date:  2009-02-15       Impact factor: 15.369

9.  Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex.

Authors:  Mark A Brown; Robert J Sims; Paul D Gottlieb; Philip W Tucker
Journal:  Mol Cancer       Date:  2006-06-28       Impact factor: 27.401

10.  Dot1 histone methyltransferases share a distributive mechanism but have highly diverged catalytic properties.

Authors:  Iris J E Stulemeijer; Dirk De Vos; Kirsten van Harten; Onkar K Joshi; Olga Blomberg; Tibor van Welsem; Marit Terweij; Hanneke Vlaming; Erik L de Graaf; A F Maarten Altelaar; Barbara M Bakker; Fred van Leeuwen
Journal:  Sci Rep       Date:  2015-05-12       Impact factor: 4.379

View more
  8 in total

Review 1.  Targeting the epigenome in malignant pleural mesothelioma.

Authors:  Kaitlin C McLoughlin; Andrew S Kaufman; David S Schrump
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.

Authors:  Nathan P Coussens; Stephen C Kales; Mark J Henderson; Olivia W Lee; Kurumi Y Horiuchi; Yuren Wang; Qing Chen; Ekaterina Kuznetsova; Jianghong Wu; Sirisha Chakka; Dorian M Cheff; Ken Chih-Chien Cheng; Paul Shinn; Kyle R Brimacombe; Min Shen; Anton Simeonov; Madhu Lal-Nag; Haiching Ma; Ajit Jadhav; Matthew D Hall
Journal:  J Biol Chem       Date:  2018-06-26       Impact factor: 5.157

Review 3.  KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.

Authors:  Besa Xhabija; Benjamin L Kidder
Journal:  Semin Cancer Biol       Date:  2018-11-16       Impact factor: 15.707

4.  Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors.

Authors:  Mao-Rong Zhu; Dao-Hai Du; Jun-Chi Hu; Lian-Chun Li; Jing-Qiu Liu; Hong Ding; Xiang-Qian Kong; Hua-Liang Jiang; Kai-Xian Chen; Cheng Luo
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

5.  Effect of SMYD3 on biological behavior and H3K4 methylation in bladder cancer.

Authors:  Xiang Wu; Qingjiang Xu; Pingzhou Chen; Chenbo Yu; Liefu Ye; Chen Huang; Tao Li
Journal:  Cancer Manag Res       Date:  2019-09-02       Impact factor: 3.989

Review 6.  Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development.

Authors:  Ye Jin; Tianjia Liu; Haoming Luo; Yangyang Liu; Da Liu
Journal:  Front Oncol       Date:  2022-03-28       Impact factor: 6.244

7.  A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes.

Authors:  Wenhan Yang; Kaiping Gao; Youhui Qian; Yongyi Huang; Qin Xiang; Cheng Chen; Qianqian Chen; Yiling Wang; Fuyuan Fang; Qihan He; Siqi Chen; Juan Xiong; Yangchao Chen; Ni Xie; Duo Zheng; Rihong Zhai
Journal:  J Hematol Oncol       Date:  2022-05-07       Impact factor: 23.168

8.  E4BP4 promotes thyroid cancer proliferation by modulating iron homeostasis through repression of hepcidin.

Authors:  Qinyi Zhou; Jun Chen; Jialin Feng; Jiadong Wang
Journal:  Cell Death Dis       Date:  2018-09-24       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.